ReviewJournal of cardiovascular electrophysiology2025
Atrial Fibrillation (AF) and Heart Failure With Preserved Ejection Fraction (HFpEF): Advances and Challenges.
Review in Journal of cardiovascular electrophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Editorial for "Free-Breathing Dynamic, Regularized, Adaptive Cluster Optimization (DRACO) Cine Cardiac MRI in Atrial Fibrillation".Journal of magnetic resonance imaging : JMRI · 2026Article
- GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.Journal of clinical medicine · 2026Article
- Atrial Fibrillation Risk Management and Emerging Therapies.Journal of clinical medicine · 2026Review
- ALYREF stabilizes MZF1 via m5C modification to exacerbate cardiac remodeling and atrial fibrillation in heart failure.Cellular and molecular life sciences : CMLS · 2026Article
- A Lumped-Parameter Cardiovascular Model for Investigating Hemodynamic Alterations During Atrial Fibrillation.Bioengineering (Basel, Switzerland) · 2026Article
- Factors Associated with Atrial Fibrillation in Heart Failure with Preserved and Mildly Reduced Ejection Fraction: A Real-World Cohort Study.Journal of clinical medicine · 2026Article
- Preserved Ejection, Lost Rhythm: A Narrative Review of the Pathophysiology and Management of Heart Failure with Preserved Ejection Fraction and Concomitant Atrial Fibrillation.Journal of clinical medicine · 2026Review
- Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis.Basic research in cardiology · 2025Article
- Integrating systemic inflammation and liver biomarkers: prognostic implications of the ferritin index in heart failure.Annals of medicine · 2025Article
- Targeting Atrial Fibrillation in HFpEF: Comparative Effectiveness of Rhythm Control Strategies and Modulatory Effects of SGLT2 Inhibitors.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This state-of-the-art review is based on the Philippe Coumel Lecture in 2024 (Figure 1). It highlights the confluence of two major cardiovascular epidemics, atrial fibrillation and heart failure, with preserved ejection fraction. In these conditions, advances in electrophysiology and heart failure physiology are intertwined and are integrated in this review. This constellation of disease states has its own unique epidemiologic features, pathophysiology, experimental and clinical mechanisms; and an increasing knowledge base with respect to clinical presentation, prognostic implications, and therapeutic options from pharmacologic advances and non-pharmacologic interventions. Major advances, continuing challenges, and future directions in this condition are described in this rapidly evolving field of scientific endeavor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.